[Therapeutic Options for the Management of Severe COVID-19: A Rheumatology Perspective]

Overview

Journal Reumatol Clin

Specialty Rheumatology

Date 2024 Apr 15

PMID 38620231

Authors

Claudia Mendoza-Pinto

Mario Garcia-Carrasco

Pamela Munguia Realpozo

Socorro Mendez-Martinez

Affiliations

Soon will be listed here.

Abstract

The novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). Acute respiratory distress syndrome, multiorgan dysfunction and thrombotic events are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a "cytokine storm", also known as cytokine release syndrome, may play a major role in the pathology of COVID-19. In addition to anti-viral therapy and supportive treatment in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed therapeutic options, including the antibody therapy that might be an immediate strategy for SARS-CoV-2 therapy.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

Lippi G, Plebani M, Henry B . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-148. PMC: 7102663. DOI: 10.1016/j.cca.2020.03.022. View

Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

Diep B, Le V, Badiou C, Le H, Pinheiro M, Duong A . IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016; 8(357):357ra124. DOI: 10.1126/scitranslmed.aag1153. View

Eloseily E, Weiser P, Crayne C, Haines H, Mannion M, Stoll M . Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2019; 72(2):326-334. DOI: 10.1002/art.41103. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

10.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

11.

Pyrc K, Bosch B, Berkhout B, Jebbink M, Dijkman R, Rottier P . Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006; 50(6):2000-8. PMC: 1479111. DOI: 10.1128/AAC.01598-05. View

12.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

13.

Gao Y, Li T, Han M, Li X, Wu D, Xu Y . Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020; 92(7):791-796. PMC: 7228247. DOI: 10.1002/jmv.25770. View

14.

Schwartz J, Padmanabhan A, Aqui N, Balogun R, Connelly-Smith L, Delaney M . Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016; 31(3):149-62. DOI: 10.1002/jca.21470. View

15.

Tanaka T, Narazaki M, Kishimoto T . Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016; 8(8):959-70. DOI: 10.2217/imt-2016-0020. View

16.

Boukhvalova M, Blanco J, Falsey A, Mond J . Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2015; 51(1):119-26. PMC: 7091900. DOI: 10.1038/bmt.2015.212. View

17.

Busund R, Koukline V, Utrobin U, Nedashkovsky E . Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002; 28(10):1434-9. DOI: 10.1007/s00134-002-1410-7. View

18.

DeDiego M, Nieto-Torres J, Regla-Nava J, Jimenez-Guardeno J, Fernandez-Delgado R, Fett C . Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2013; 88(2):913-24. PMC: 3911641. DOI: 10.1128/JVI.02576-13. View

19.

Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin J, Sutton S . Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. Med. 2020; 1(1):114-127.e3. PMC: 7274588. DOI: 10.1016/j.medj.2020.06.001. View

20.

Michot J, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F . Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol. 2020; 31(7):961-964. PMC: 7136869. DOI: 10.1016/j.annonc.2020.03.300. View